Capoten in kidney disease
Executive Summary
400-patient, 24-center study funded by Squibb Institute for Medical Research and National Institute of Diabetes and Digestive and Kidney Diseases is under way. Previous research suggests that inhibition of angiotensin converting enzyme lowers blood pressure within the kidney's filtering system, preventing injury to the small blood vessels. Study is expected to last four years.
You may also be interested in...
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.